In:
Blood, American Society of Hematology, Vol. 124, No. 2 ( 2014-07-10), p. 204-210
Kurzfassung:
Patients with a history of acquired TTP and persistent severe ADAMTS13 deficiency during remission are at high risk of relapse and death. Preemptive infusions of rituximab in remission significantly decrease TTP relapse rate.
Materialart:
Online-Ressource
ISSN:
0006-4971
,
1528-0020
DOI:
10.1182/blood-2014-01-550244
Sprache:
Englisch
Verlag:
American Society of Hematology
Publikationsdatum:
2014
ZDB Id:
1468538-3
ZDB Id:
80069-7